MediPharm Labs Corp., a Canadian pharmaceutical company specializing in cannabinoid products, has started production of cannabis metered dose inhalers for the European Union and the United Kingdom. This initiative is part of a sales and distribution agreement with Blackpoint Limited, which will handle distribution in these regions.
The metered dose inhalers are designed to meet global pharmaceutical standards, offering patients a discreet and smoke-free method for rapid relief. Unlike traditional smoking methods, these inhalers allow for the delivery of precise doses of cannabis active pharmaceutical ingredients (API) without the risks associated with combustion or vaporization.
Manufactured under Good Manufacturing Practices (GMP), these inhalers utilize GMP-qualified components to ensure quality and safety for medical use. MediPharm Labs has previously introduced metered dose inhalers in Canada and plans to expand to Australia, the EU, and the UK by the third quarter of 2025.
David Pidduck, CEO of MediPharm Labs, expressed enthusiasm about the international expansion, stating, “We’re excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This product aligns with our mission to enhance access to pharmaceutical-grade cannabinoid wellness products.”
Blackpoint’s CEO, David Martinez, also shared his optimism about the partnership, emphasizing the importance of these inhalers for patients in the EU and UK markets.
Key aspects of the launch include: – Exclusive Supply Agreement: MediPharm Labs is the sole supplier of the metered dose inhalers to Blackpoint, which ensures a consistent product supply in the designated markets. Prohibition Partners estimates that the European medicinal cannabis market will reach €834 million in 2024, highlighting the potential for growth. – Innovative Delivery Method: The inhalers deliver a consistent and repeatable dose of cannabis API, which can lead to reliable patient outcomes without the negative aspects of smoking or vaping. – GMP Manufacturing Standards: The inhalers are produced under rigorous GMP standards, which are crucial for maintaining high quality and safety in medical applications. – Medical Use: The inhaler format is familiar to many patients, similar to those used for asthma treatments, which can enhance user acceptance and compliance.
MediPharm Labs is well-positioned to tap into the growing demand for cannabis-based medical products in Europe, leveraging its manufacturing capabilities and established relationships within the industry.
English 
Spanish 
German 
Czech